Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain

Journal of Virology

Volumn 76, Issue 16, 2002, Pages 8446-8454

  Mastakov, Mihail Y ^a   Baer, Kristin ^a   Symes, C Wymond ^a   Leichtlein, Claudia B ^a   Kotin, Robert M ^a   During, Matthew J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GENE PRODUCT; MANNITOL;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; CONTROLLED STUDY; GENE SEQUENCE; GENE THERAPY; GENETIC CODE; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; MAMMAL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BRAIN; CAPSID; DEPENDOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; INJECTIONS; LUMINESCENT PROTEINS; MALE; NEUTRALIZATION TESTS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 0036315299     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.16.8446-8454.2002     Document Type: Article

References (54)

1. Additional transduction events after subretinal readministration of recombinant adeno-associated virus
2. Repeated delivery of adeno-associated virus vectors to the rabbit airway
3. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
4. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
5. Interactions between the immune system and gene therapy vectors: Bidirectional regulation of response and expression
6. Reproducible and efficient murine CNS gene delivery using a microprocessor controlled injector
7. Recombinant adeno-associated virus vector: Use for transgene expression and anterograde tract tracing in the CNS
8. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
9. Cloning and characterization of adeno-associated virus type 5
10. Immune responses to adenovirus and adeno-associated virus in humans
11. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
12. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses
13. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle
14. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies
15. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors
16. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
17. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
18. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
19. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
20. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
21. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of f9
22. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
23. Recombinant adeno-associated virus for muscle directed gene therapy
24. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
25. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX
26. Novel tools for production and purification of recombinant adenoassociated virus vectors
27. Repeat transduction in the mouse lung hy using adeno-associated virus vectors with different serotypes
28. Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
29. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure
30. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model
31. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
32. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer
33. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
34. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice
35. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
36. Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression
37. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors
38. Combined injection of rAAV with mannitol enhances gene expression in the rat brain
39. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector
40. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotypc for long-term liver-directed gene transfer in baboons
41. Epilope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure
42. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3
43. Efficient selection for high-expression transfectants with a novel eukaryotic vector
44. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
45. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors
46. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
47. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors
48. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2 cell interaction and neutralization of AAV-2 infection
49. Gene therapy vectors based on adeno-associated virus type 1
50. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
51. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
52. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain specific gene cassettes
53. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective